Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors.
about
Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor.Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safetyIn vitro and in vivo pharmacological profile of the 5-benzyl analogue of 14-methoxymetopon, a novel mu opioid analgesic with reduced propensity to alter motor functionCYP2D6 in the metabolism of opioids for mild to moderate pain.CYP2D6 genotype dependent oxycodone metabolism in postoperative patients.Effects of μ-opioid receptor agonists in assays of acute pain-stimulated and pain-depressed behavior in male rats: role of μ-agonist efficacy and noxious stimulus intensity.Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists.Pharmacogenetics of analgesic drugsDesign, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.Complicated pain management in a CYP450 2D6 poor metabolizer.Role of µ-opioid receptor reserve and µ-agonist efficacy as determinants of the effects of µ-agonists on intracranial self-stimulation in rats6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand.Evidence from basic research for opioid combinations.Opioid genetics: the key to personalized pain control?Central HIV-1 Tat exposure elevates anxiety and fear conditioned responses of male mice concurrent with altered mu-opioid receptor-mediated G-protein activation and β-arrestin 2 activity in the forebrain.Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats.Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine.Application of receptor theory to the design and use of fixed-proportion mu-opioid agonist and antagonist mixtures in rhesus monkeys.Analgesic Plasma Concentrations of Oxycodone After Surgery for Breast Cancer-Which Factors Matter?Linking Aromatic Hydroxy Metabolic Functionalization of Drug Molecules to Structure and Pharmacologic Activity
P2860
Q34001543-2907B3F0-4681-4570-8C9D-FB3D92426AEFQ34019354-2F3FD7C6-459F-4CB8-ACED-2731ABBA59C0Q34123368-EEA825FC-357F-4A1F-8D7C-8C5265D8F003Q34124185-B3BB6413-1D01-4B98-80AD-376CF8612D9BQ34178485-27D83B23-1462-42EB-9A7F-04F858467539Q34653610-0E4C9479-84CF-4B80-87CB-FAB7F8FBF740Q34946659-A0A556DC-FBF9-4328-B4EC-88F9CBF3F766Q36015414-DD578E9F-78C6-4E0D-B560-CA64A11F3D30Q36110592-046000AD-4A58-458D-A957-236DFE91A394Q36480105-3A164C8A-FEBE-4FD3-BFF3-5D88E124E024Q36994597-C0EB3039-D93A-40D5-84FF-17884BB68DCAQ37394355-ED25D7F4-08A0-496E-A539-B84D2BB9A065Q37444418-BB2BB752-4C63-49D3-AB4F-0B8434A9D803Q37999097-0BA080A7-29F6-476F-B31C-DC0850627BE0Q38025200-A60C6CD2-B9C3-462E-B5AA-142706A10F32Q42715611-571CC896-A39A-4B3C-99B1-C164EF199BBAQ45051146-02D75F34-84A5-4166-A1C0-0D226C33A61EQ47373258-980D036B-14C0-4EB5-80E1-5ABC410DC6F1Q47718621-07A00B42-66EE-4A1A-9C12-7DA3B300645CQ50568090-D89888C7-9336-42E9-B115-1C1CF638AB99Q58691462-D4D6D8F5-E294-4167-94CC-B932C5A65FA9
P2860
Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors.
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Activation of G-proteins by mo ...... u- and delta-opioid receptors.
@ast
Activation of G-proteins by mo ...... u- and delta-opioid receptors.
@en
Activation of G-proteins by mo ...... u- and delta-opioid receptors.
@nl
type
label
Activation of G-proteins by mo ...... u- and delta-opioid receptors.
@ast
Activation of G-proteins by mo ...... u- and delta-opioid receptors.
@en
Activation of G-proteins by mo ...... u- and delta-opioid receptors.
@nl
prefLabel
Activation of G-proteins by mo ...... u- and delta-opioid receptors.
@ast
Activation of G-proteins by mo ...... u- and delta-opioid receptors.
@en
Activation of G-proteins by mo ...... u- and delta-opioid receptors.
@nl
P2093
P356
P1476
Activation of G-proteins by mo ...... u- and delta-opioid receptors.
@en
P2093
Chad M Thompson
Dana E Selley
Elisabeth Greiner
Everette L May
Heidi Wojno
Kenner C Rice
P304
P356
10.1124/JPET.103.058602
P407
P577
2003-11-04T00:00:00Z